SEC Form 4 · accession 0001209191-15-083422
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yuchun Lee
Director
Period of report
Dec 1, 2015
Accepted (ET)
Dec 3, 2015 · 9:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 1, 2015 | M | 1,333 | $57.27 | A | 1,958 | D | |
| Common StockF2,F3 | Dec 1, 2015 | S | 400 | $128.77 | D | 1,558 | D | |
| Common StockF2,F4 | Dec 1, 2015 | S | 625 | $129.97 | D | 933 | D | |
| Common Stock | Dec 1, 2015 | S | 100 | $131.21 | D | 833 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $57.27 | Dec 1, 2015 | M | 1,333 | D | — | Sep 13, 2022 | Common Stock | 1,333 | 24,667 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
- F2Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $128.77 (range $128.37 to $129.09).
- F4Open market sales reported on this line occurred at a weighted average price of $129.97 (range $129.64 to $130.60).
- F5The option vests in 16 quarterly installments from 09/14/2012.